New Recommendations for a Thyroid and Cardiovascular Disease Research Agenda have been co-published in Thyroid and Circulation. The Guidelines are publish online here in Thyroid. The Guidelines are also copyrighted by the American Heart Association and are being simultaneously publish in its journal Circulation.
Thyroid hormones have long know to have a range of effects on the cardiovascular system. However, significant knowledge gaps exist concerning the precise molecular and biochemical mechanisms governing these effects and the optimal strategies for management of abnormalities in thyroid function in patients with and without preexisting cardiovascular disease.
The thyroid dysfunction
In September 2017, The National Heart, Lung, and Blood Institute convene a Working Group with the goal of developing priorities for future scientific research relating thyroid dysfunction to the progression of cardiovascular disease. Thyroid and Cardiovascular Disease: Research Agenda for Enhancing Knowledge, Prevention, and Treatment; hence presents the results of an international working group convene by the U.S.
National Heart, Lung, and Blood Institute (NHLBI) responsible for developing research priorities; so relating thyroid dysfunction to the progression of cardiovascular disease. Led by Anne Cappola, MD, Perelman School of Medicine at the University of Pennsylvania, coauthors; so include researchers from Brigham and Women’s Hospital, Erasmus Medical Center, the National Heart, Lung, and Blood Institute, New York University School of Medicine, University of Arizona.
The expert scientists and clinicians discuss how thyroid function; also thyroid therapy impact various aspects of cardiovascular disease, including arrhythmias, atherosclerosis, and heart failure. These discussions led to recommendations in three broad areas; so including identification of novel biomarkers of thyroid action in cardiovascular tissues; hence defining subgroups of patients suitable for preventive and therapeutic approaches, and clinical trials involving thyroid medications that can improve cardiovascular performance and outcomes.
The intriguing physicians
The connection between thyroid and cardiac function has intriguing physicians for more than a century. This multidisciplinary international working group convene by the NHLBI has identify key areas where further research may provide fundamental new insights into this connection, and these recommendations will be stimulating for numerous investigators interest in this field, says Peter A. Kopp.
There are no prospective, randomize trials of thyroid hormone supplementation in patients with chronic heart failure with reduce ejection fraction or preserve ejection fraction and low serum T3 levels, and there is limit understanding of the optimal thresholds for therapy of thyroid hormone abnormalities in patients with establish heart failure.
Based on discussion at the meeting, the Working Group; which define three broad recommendations for research activity. The first set of recommendations focuses on basic biology. The second and third recommendations, with their focus on refining thresholds and testing treatment strategies in clinical trials; so have more immediate translational potential.